Literature DB >> 27686238

Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.

W Hartwig1,2, A Gluth1,2, U Hinz1, D Koliogiannis1,2, O Strobel1, T Hackert1, J Werner1,2, M W Büchler3.   

Abstract

BACKGROUND: In the recent International Study Group of Pancreatic Surgery (ISGPS) consensus on extended pancreatectomy, several issues on perioperative outcome and long-term survival remained unclear. Robust data on outcomes are sparse. The present study aimed to assess the outcome of extended pancreatectomy for borderline resectable and locally advanced pancreatic cancer.
METHODS: A consecutive series of patients with primary pancreatic adenocarcinoma undergoing extended pancreatectomies, as defined by the new ISGPS consensus, were compared with patients who had a standard pancreatectomy. Univariable and multivariable analysis was performed to identify risk factors for perioperative mortality and characteristics associated with survival. Long-term outcome was assessed by means of Kaplan-Meier analysis.
RESULTS: The 611 patients who had an extended pancreatectomy had significantly greater surgical morbidity than the 1217 patients who underwent a standard resection (42·7 versus 34·2 per cent respectively), and higher 30-day mortality (4·3 versus 1·8 per cent) and in-hospital mortality (7·5 versus 3·6 per cent) rates. Operating time of 300 min or more, extended total pancreatectomy, and ASA fitness grade of III or IV were associated with increased in-hospital mortality in multivariable analysis, whereas resections involving the colon, portal vein or arteries were not. Median survival and 5-year overall survival rate were reduced in patients having extended pancreatectomy compared with those undergoing a standard resection (16·1 versus 23·6 months, and 11·3 versus 20·6 per cent, respectively). Older age, G3/4 tumours, two or more positive lymph nodes, macroscopic positive resection margins, duration of surgery of 420 min or above, and blood loss of 1000 ml or more were independently associated with decreased overall survival.
CONCLUSION: Extended resections are associated with increased perioperative morbidity and mortality, particularly when extended total pancreatectomy is performed. Favourable long-term outcome is achieved in some patients.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27686238     DOI: 10.1002/bjs.10221

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  24 in total

1.  Perioperative Complications and Outcomes after Intestinal Autotransplantation for Neoplasms Involving the Superior Mesenteric Artery.

Authors:  Guosheng Wu; Qingchuan Zhao; Xiaohua Li; Mian Wang; Hao Sun; Jingson Zhang; Zengshan Li; Jianyong Zheng; Mengbin Li; Daiming Fan
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

2.  An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era.

Authors:  Marc W Fromer; Jenci Hawthorne; Prejesh Philips; Michael E Egger; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Ann Surg Oncol       Date:  2021-06-04       Impact factor: 5.344

3.  Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?

Authors:  Laurent Sulpice; Olivier Turrini; Jonathan Garnier; Fabien Robin; Jacques Ewald; Ugo Marchese; Damien Bergeat; Karim Boudjema; Jean-Robert Delpero
Journal:  Ann Surg Oncol       Date:  2021-01-18       Impact factor: 5.344

Review 4.  Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.

Authors:  Hideyuki Yoshitomi; Shigetsugu Takano; Katsunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Masayuki Ohtsuka
Journal:  Surg Today       Date:  2019-04-04       Impact factor: 2.549

5.  Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors.

Authors:  Abhishek Mitra; Esha Pai; Rohit Dusane; Priya Ranganathan; Ashwin DeSouza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2018-01-23       Impact factor: 3.445

6.  Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer.

Authors:  Masaru Miyazaki; Hideyuki Yoshitomi; Shigetsugu Takano; Hiroaki Shimizu; Atsushi Kato; Hiroyuki Yoshidome; Katunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Daisuke Suzuki; Nozomu Sakai; Masayuki Ohtuka
Journal:  Langenbecks Arch Surg       Date:  2017-03-30       Impact factor: 3.445

Review 7.  Pancreatoduodenectomy associated with colonic resections: indications, pitfalls, and outcomes.

Authors:  Tommaso Giuliani; Anthony Di Gioia; Stefano Andrianello; Giovanni Marchegiani; Claudio Bassi
Journal:  Updates Surg       Date:  2021-02-13

8.  Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study.

Authors:  Baobao Cai; Zipeng Lu; Markus W Büchler; Yi Miao; John P Neoptolemos; Markus K Diener; Mingna Li; Lingdi Yin; Yong Gao; Jishu Wei; Jianmin Chen; Feng Guo; Min Tu; Chunhua Xi; Junli Wu; Wentao Gao; Cuncai Dai; Kuirong Jiang
Journal:  Langenbecks Arch Surg       Date:  2021-01-28       Impact factor: 3.445

9.  Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression.

Authors:  Ryo Saito; Hiromichi Kawaida; Naohiro Hosomura; Hidetake Amemiya; Jun Itakura; Atsushi Yamamoto; Koichi Takiguchi; Suguru Maruyama; Katsutoshi Shoda; Shinji Furuya; Hidenori Akaike; Yoshihiko Kawaguchi; Makoto Sudo; Shingo Inoue; Hiroshi Kono; Daisuke Ichikawa
Journal:  Ann Surg Oncol       Date:  2021-06-08       Impact factor: 5.344

10.  A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy.

Authors:  Ho Kyoung Hwang; Keita Wada; Ha Yan Kim; Yuichi Nagakawa; Yosuke Hijikata; Yota Kawasaki; Yoshiharu Nakamura; Lip Seng Lee; Dong Sup Yoon; Woo Jung Lee; Chang Moo Kang
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.